University of Miami Sylvester Comprehensive Cancer Center , a Long-Time EDAP Ablatherm® User, to Upgrade to the Most Advanced HIFU Technology for the Treatment of Prostate Disease Focal One Successfully Launched with Several Patients Treated to Date LYON, France , January 29, 2020 – EDAP TMS SA
Recaps significant progress made in 2019 and previews expectations for accelerating global growth in 2020 LYON, France , January 9, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in Robotic Energy-based Therapies, today issued the following letter to shareholders: To my
Study confirms feasibility of using Focal One HIFU to treat rectal endometriosis LYON, France , December 19, 2019 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in therapeutic ultrasound, today announced that Focal One data has been accepted for publication in the journal of
Farrer Park Hospital becomes the first hospital in Southeast Asia to implement Focal One ® EDAP poised to expand HIFU in Southeast Asia LYON, France , November 26, 2019 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in therapeutic ultrasound, announced today that the first Focal
67.8% growth in HIFU revenue through the nine month period ended September 30 over the comparable period in 2018 48.2% Gross margin for the nine month period ended September 30 compared to 42.3% for the comparable period in 2018 Fourth consecutive quarter of profitability Continued to drive US
New Endo-UP® Platform, featuring innovative stone management technologies, to be unveiled EDAP’s cutting edge High Intensity Focused Ultrasound (HIFU) and Extracorporeal Shockwave Lithotripsy (ESWL) technologies will also be showcased LYON, France , October 30, 2019 -- EDAP TMS SA
Company to host conference call and webcast on Thursday, November 14 , at 8:30 am EDT LYON, France , October 24, 2019 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the third quarter and nine months ended
Third consecutive profitable quarter Positive reimbursement decision by the American Medical Association announced in June Significant improvement in gross profit margin from 41.3% in Q2 2018 to 50.7% in Q2 2019 Q2 HIFU sales growth of 98% year-over-year Total Q2 revenues of EUR 12.5 million ; +45%
45% growth in total Q2 2019 revenue year-over-year 78% growth in HIFU sales year-to-date through June 30, 2019 Company to Report Second Quarter 2019 Financial Results on Wednesday, August 28, 2019 and to host conference call and webcast on Thursday August 29 , at 8:30 am EDT LYON, France , July
AMA allocates a new Category 1 CPT code for High Intensity Focused Ultrasound (HIFU) Definitive CPT code will cover the transrectal ablation of malignant prostate tissue with HIFU including ultrasound guidance LYON, France , June 10, 2019 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”) , the global
